

Supplementary table 3. Individual risk factors, Forest plots, decisions of the expert panel

Study design	Size: Number of children	Outcome	Decision rules
<ul style="list-style-type: none"> ◆ Cohort ● Case-control ■ Cross-sectional <p>Quality scores by names of papers</p>	<ul style="list-style-type: none"> ● <1,000 ● 1,001 – 10,000 ● >10,001 	<ul style="list-style-type: none"> — Combination outcome — Hospitalisation — ED visit — Oral steroid (OCS) course — Urgent/unscheduled care 	<p>OR <1.1 no effect, 1.1-1.5 slightly increased risk, 1.5-2.5 moderately increased risk, >2.5 greatly increased risk</p> <p>Interpretation based on number, design and quality of studies, consistency of results, biological plausibility.</p>


Note: the scale on all the Forest plots has been curtailed at an OR of 8 to enable comparison between the plots for the different factors. If the confidence intervals are very wide, and the upper limit extends beyond the plot this is indicated with a line with an arrow. (95%CI are given in table 2 if required)

Greatly increased risk

Previous attacks		
Odds ratios plotted on a Forest plot	Results not possible to plot	Conclusions
<p>Logistic regression: OR (95% CI)</p>	<ul style="list-style-type: none"> ■ Engelkes 2016 (cohort 7/9) prior attack(s) increase risk RR 1.99 (1.40 to 2.83) ■ Wu 2011 (cohort 6/9): Prior exacerbation increases risk (P<0.001) ■ Forno 2010 (cross-sectional; 7/10): Prior OCS course increases risk (P<0.001) ■ Quezada 2016 (cross-sectional; 6/10): Prior OCS course/attack increased risk (P<0.001 or P<0.01) ■ Butz 2000 (cross-sectional; 4/10): Prior nebuliser use increases risk (P<0.001) 	<p>Evidence base: 8 cohort studies 3 cross sectional studies</p> <p>Consistent findings: all studies show an increased risk</p> <div style="background-color: #a52a2a; color: white; padding: 5px; text-align: center;"> <p>Greatly increased risk Highly confident</p> </div>

Persistent symptoms

Odds ratios plotted on a Forest plot



VPC = very poor control; d=day; w=week;

Results not possible to plot

- Robroeks (cohort; 9/9): poor asthma control increases risk (p=0.007)
- Kwong 2012 (cohort; 6/9): well-controlled or mild intermittent (but not mild persistent) asthma reduces risk compared to severe persistent asthma
- Halterman 2001 (cohort 5/9): no significant difference between intermittent and persistent asthma in ED visits and OCS use
- Canino 2012 (cross-sectional; 2/10): unclear outcome

Conclusions


Evidence base:
 5 cohort studies
 1 case-control
 5 cross sectional studies

Consistent findings in the higher quality, larger, more robust study designs. Persistent symptoms are associated with an increased risk

Moderately/greatly increased risk
Highly confident

Poor access to healthcare

Odds ratios plotted on a Forest plot



Results not possible to plot

- Halterman 2001 (Cohort, 5/9): no increased risk (Medicaid vs no Medicaid)
- Wood 2002 (cross-sectional, 5/10): increased risk with poor access to care (3 of 4 results significant)
- Canino 2012 (cross-sectional, 3/10): increased risk with public insurance and lack of usual care

Conclusions

Evidence base:
 1 cohort study
 4 cross sectional studies

Consistent findings in most studies. US based studies, access defined by healthcare arrangements

Moderately/greatly increased risk

Moderately confident

Moderately increased risk


Sub-optimal medication regime (low ratio of inhaled steroid (ICS) to total asthma medication)		
Odds ratios plotted on a Forest plot	Results not possible to plot	Conclusions
<p>Legend:</p> <ul style="list-style-type: none"> Baltrus 2017 (9/9) Controller/total med ratio < 0.5 Andrews 2013 (8/9) Controller/total med ratio < 0.5 Zhang 2013 (8/9) Suboptimal drug regimen Farber 2004 (7/9) Suboptimal drug regimen Rust 2013 (9/10) Controller/total med ratio < 0.5 Rust 2013 (9/10) Controller/total med ratio < 0.5 <p>Logistic regression: OR (95% CI)</p>	<ul style="list-style-type: none"> Spahn 2009 (cohort 6/9): ICS use in summer had lower autumn hospitalisations than non-users Engelkes 2016 (Cohort, 6/9): increased risk (prior asthma treatment) Farber 2004 (cohort, 8/9): No effect on exacerbations (controller/total ratio) Schatz 2003 (cohort, 6/9): no effect on hospitalization (ICS/total ratio) Vernaccio 2013 (cross-sectional, 8/10): increased risk (no/low controller ratio) 	<p>Evidence base: 7 cohort studies 2 cross sectional studies</p> <p>Consistent findings in most studies.</p> <p>Moderately increased risk Highly confident</p>

Co-morbid atopic/allergic disease (Allergic rhinitis, eczema, and food allergy)

Odds ratios plotted on a Forest plot

Results not possible to plot

Conclusions



- Engelkes 2016 (Cohort, 7/9): No effect (asthma + allergic rhinitis, or eczema)
- Pinto-Pereira 2010 (cross-sectional, 6/10): increased risk (asthma + allergic rhinitis)


Evidence base:
2 cohort studies
4 cross sectional studies

Most, studies showed an increased risk in children with one or more co-morbid atopic conditions. No consistent difference between the different conditions, or between one, two or three conditions

Moderately increased risk
Slightly confident

African-American ethnicity

Odds ratios plotted on a Forest plot



Results not possible to plot

- Halterman 2001 (cohort, 5/9): not significant (Black vs non-Black)
- Malhotra (cross-sectional, 6/10): increased risk in populations with high ratio of Black/White
- Quezada (cross-sectional, 6/10): not significant (Black vs Others)
- Wood 2002 (cross-sectional, 5/10): increased risk (Black vs Hispanic)

Conclusions


Evidence base:
4 cohort studies
8 cross sectional studies

Consistent findings in the higher quality, more robust study designs. All these studies were in the US

Moderately increased risk
Highly confident

Vitamin D deficiency

Odds ratios plotted on a Forest plot



Results not possible to plot

- Brehm 2012 (Cross-sectional, 9/10): no effect of high vitamin D intake
- Searing (cross-sectional, 5/10): increased risk associated with vitamin D deficiency

Conclusions


Evidence base:
1 cohort
1 case control study
2 cross sectional studies

Small studies

Moderately increased risk
Slightly confident

Poverty

Odds ratios plotted on a Forest plot



Results not possible to plot

- Schatz 2003 (cohort, 6/9): reduced risk (lower family income) $P < 0.05$
- Lieu 1997 (case-control, 7/9): as annual income increased, hospitalisation odds decreased.
- Wood 2002 (cross-sectional, 5/10): increased risk (people denied benefits) no effect (people on benefits)
- Canino 2012 (cross-sectional, 2/10): increased risk (poverty and neighbourhood risk)

Conclusions

Evidence base:
 1 cohort study
 2 case control
 6 cross sectional studies

Most studies showed an increased risk in children living in low income families.

Moderately increased risk

Moderately confident


Slightly increased risk

Exposure to environmental tobacco smoke (ETS)		
Odds ratios plotted on a Forest plot	Results not possible to plot	Conclusions
<p>Legend:</p> <ul style="list-style-type: none"> Pyle 2015 (6/9) ETS exposure at home (red) Pyle 2015 (6/9) ETS exposure at home (blue) Pyle 2015 (6/9) ETS exposure at home (green) Rosas Salazar 2013 (9/10) ETS exposure (black) Dales 2002 (7/10) Regular ETS exposure (black) <p>Logistic Regression: ORs (95% CI)</p>	<ul style="list-style-type: none"> ■ Rabinovitch 2011 (cohort, 6/9): increased risk (reported and/or cotinine) ■ McCarville 2013 (cross-sectional, 8/10): increased risk (cotinine level); no effect (parental report) ■ Chilmonczyk 1993 (cross-sectional, 7/10): No effect (parental or cotinine report) ■ Quezada 2016 (cross-sectional, 6/10): No effect (parental report) ■ Canino 2012 (cross-sectional, 2/10): increased risk (reported ETS exposure) 	<p>Evidence base: 1 cohort 1 case-control 6 cross sectional studies</p> <p>Discrepancy between risk associated with parental report and elevated cotinine.</p> <p>Slightly increased risk Highly confident</p>

Younger children within the 5-12 age range		
Odds ratios plotted on a Forest plot	Results not possible to plot	Conclusions
<p>Insufficient ORs to plot</p>	<ul style="list-style-type: none"> ■ Baltrus 2017 (cohort 9/9): reduced risk with increased age ■ Schatz 2003 (cohort, 6/9): increased risk (younger age) $P < 0.001$ ■ Murray 1997 (cohort study 6/9): increased risk 5-9yr olds vs 10-14yr olds ■ Sarpong 1997 (cross-sectional 8/10): each year of age reduced OR 0.77 (0.67 to 0.90) ■ Quezada 2016 (cross-sectional 6/10): increased risk ■ Wood 2002 (cross-sectional 5/10): increased risk 	<p>Evidence base: 3 cohort studies 3 cross sectional studies</p> <p>Consistent finding of increased risk in younger children.</p> <p>Slightly increased risk Highly confident</p>

Obesity/overweight

Odds ratios plotted on a Forest plot



Definitions: Obese BMI>95th percentile; Overweight BMI>85th percentile; Underweight BMI<5th percentile

Results not possible to plot

- Peters 2011 (cohort 8/9) 'No effect in the regression analysis'
- Black 2013 (cohort 8/9) increased risk
- Wu 2011 (cohort 6/9) No effect
- Mahut 2012 (cross sectional 7/10) no effect
- Quezada 2016 (cross sectional 6/10) No effect
- Stingone 2011(cross sectional 6/10) increased risk

Conclusions


Evidence base:
4 cohort studies
6 cross sectional studies

Consistent finding of slightly increased risk in large population level studies

Slightly increased risk
Highly confident

Low parental education level

Odds ratios plotted on a Forest plot



Results not possible to plot


- Lieu 1997 (case-control, 7/9): as father's education increased, odds of having ED visit decreased

Conclusions

Evidence base:
1 case control study
3 cross sectional studies
All studies have at least one positive outcome

Slightly increased risk. Moderately confident

Reliever medication use



- Vernachio 2013 (cross-sectional 9/10) Increased risk (≥ 4 SABA) prescriptions/year. No effect (≤ 3 SABA/year)
- Quezada (cross-sectional 6/10) Increased risk (>2 doses reliever a week)

Evidence base:
 3 Cohort
 1 case control
 3 cross-sectional studies


Relatively low doses of SABA; no data on very high doses

Slightly increased risk
Moderately confident

No increased risk

Gender		
Odds ratios plotted on a Forest plot	Results not possible to plot	Conclusions
<p>Logistic Regression: ORs (95% CI)</p>	<p>No significant gender difference:</p> <ul style="list-style-type: none"> ■ Engelkes 2016 (cohort 7/9) ■ Schatz 2003 (cohort 6/9) ■ Akinbami 2009 (cross-sectional 6/10) ■ Halterman 2001 (cross-sectional 5/10) ■ Quezada 2016 (cross sectional 6/10) ■ Canino 2012 (cross sectional 2/10) <p>Boys at greater risk:</p> <ul style="list-style-type: none"> ■ McCarville 2013 (cross sectional 8/10) 	<p>Evidence base: 5 cohort 9 cross-sectional studies</p> <p>Consistent finding of no gender difference</p>
		Not a risk factor Highly confident

Hispanic ethnicity (US studies)



- Kwong 2012 (cohort 6/9): not significant compared to white population
- McCarville 2013 (cross-sectional, 8/10): not significant results (Hispanic vs non-Hispanic)

Evidence base:
3 cohort studies
6 cross sectional studies

Consistent findings in the higher quality, more robust study designs. All these studies were in the US

No consistent effect

Moderately confident

Urban residence/proximity to major road

Odds ratios plotted on a Forest plot

Results not possible to plot

Conclusions

Insufficient ORs to plot

- Halterman 2001 (cohort 5/9) no increased risk of living in urban location
- Blatter 2016 (case-control 7/9) increased risk per 100m from major road
- Rust 2013 (cross-sectional 9/10) no increased risk of living in large metropolitan area (n=43,156)
- Pesek 2010 (cross-sectional 8/10) no increased risk of living in urban location
- Sarpong 1997 (cross-sectional 8/10) no increased risk of living in urban location
- Brown 2012 (cross-sectional 7/10) proximity to major road increased risk of hospitalisations but not ED visits.

Evidence base:
1 cohort
1 case control
4 cross-sectional studies

5 studies, including a large high quality cross-sectional study showed no increased risk with urban residence or proximity to major roads.

Not a risk factor

Moderately confident

Confounded by severity/indication

Controller medication use	Evidence base: 6 Cohort 2 case control 8 cross-sectional studies	Confounded by indication
In 9 of the 16 studies, ICS use was associated with an increased exacerbation risk. In 3 studies ICS use was associated with no difference in exacerbation risk In 3 studies ICS use was associated with a reduction in exacerbation risk		
Nebuliser use		
Odds ratios plotted on a Forest plot	Results not possible to plot	Conclusions
Insufficient ORs to plot	<ul style="list-style-type: none"> ■ Lieu 1997 (Case-control, 7/9) Increased risk with ownership of a nebuliser ■ Butz 2000 (Cross-sectional, 4/10) Increased risk with use of nebuliser 	Evidence base: 1 case control study 1 cross sectional studies
Ownership of written asthma management plan	Evidence base: 1 case control 1 cross-sectional studies	Confounded by indication
One study found that action plan was associated with an increased risk and one with a reduced risk		
Routine asthma reviews	Evidence base: 1 cohort 2 cross-sectional studies	Confounded by severity
All three studies showed that attendance at routine checks was associated with increased risk of exacerbations		

Inconclusive

<p>Reduced lung function</p>	<p>Evidence base: 3 cohort studies 1 case control study 3 cross sectional</p>	<p>Inconclusive</p>
<p>5 small studies (N<500) with inconsistent findings; the larger cohort study (n=1019) had mixed results 1 cross-sectional study (n=1,041) found that reduced pre-bronchodilator FEV₁ was associated with increased attacks 'at any time during the child's life'. As this outcome included pre-school admissions, potentially confounded with viral associated wheeze, it was unclear whether this reflected the situation in children 5-12yrs.</p>	<p>Evidence base: 3 cohort studies</p>	<p>Inconclusive</p>
<p>FeNO testing at routine reviews</p>	<p>Evidence base: 1 cohort 1 case control 2 cross-sectional studies</p>	<p>Inconclusive</p>
<p>In 2 of the 3 studies, both in small cohorts with relatively severe asthma, FeNO tested at regular visits (2 or 3 monthly) did not predict attacks in the subsequent 2 – 3 months. In 1 study, median FeNO at baseline predicted exacerbations in the subsequent year, but was clinically unhelpful because of overlap of FeNO levels in the two groups.</p>	<p>Positive skin prick test (SPT)</p>	<p>Inconclusive</p>
<p>In the cohort study (n=1,019) and the case control study (n=304), a positive SPT was not associated with an increased risk. In one of the cross-sectional studies a positive SPT (to cat or cockroach) was associated with an increased risk, but a positive SPT to HDM or dog was not. The other showed an association of a positive SPT on ED visits, but not oral steroids courses.</p>	<p>Evidence base: 3 cohort 2 cross-sectional studies</p>	<p>Inconclusive</p>
<p>History of allergen exposure</p>	<p>Inconsistent outcomes to exposure to cockroach, mouse, fungal spores, cats/dogs The larger cross-sectional study (n=2,966) showed an association of attacks with dogs, but not cats; the much smaller cross-sectional study (n=86) showed an association with cockroach infestation. The three cohort studies had mixed outcomes.</p>	<p>Inconclusive</p>

Insufficient evidence

Serum total IgE	Evidence base: 1 cohort 1 cross-sectional study	Insufficient
Limited evidence and inconsistent outcomes: The cohort study (n=1,019) was negative; the cross-sectional study (n=465) was positive		
Family history of atopy	Evidence base: 1 cohort 1 cross-sectional study	Insufficient
Limited evidence and inconsistent outcomes The cohort study (n=1,019) was negative; the cross-sectional study (n=465) was positive for paternal hay fever but not for any other family history of atopic conditions.		
Age of onset of asthma	Evidence base: 1 cross-sectional study	Insufficient
Limited inconclusive findings One small (n=200) cross-sectional study showed no association with attacks		
Duration of asthma	Evidence base: 1 cohort 2 cross-sectional studies	Insufficient
No consistent effect of duration of asthma The cohort study (n=563) was positive, one cross-sectional study was negative. One study confounded by duration of the outcome (Prior hospitalisation at any time during their life).		
Co-morbidities	Evidence base: 1 cross-sectional study	Insufficient
Limited inconclusive findings (for Gastro-oesophageal reflux, or diabetes) One very large (n=32,321) showed a positive association of diabetes or GORD with hospitalisations but not oral steroids.		
IQ/special needs	Evidence base: 2 cross-sectional study	Insufficient
Limited inconclusive findings The larger study (n=1,041) was positive but used the unclear outcome 'Prior hospitalisation at any time during their life' and the smaller study was positive for hospitalisations but not ED visits		
Parental health	Evidence base: 1 cross-sectional study	Insufficient
Limited inconclusive findings One positive moderate quality cross-sectional study (n=386)		
Parental marital status	Evidence base: 2 cross-sectional study	Insufficient
Limited inconclusive findings Two moderate quality cross-sectional studies. The larger (n=2,986) was positive for single parent families, but not for separated, divorced or widowed. The smaller study was negative (n=386)		